<DOC>
	<DOCNO>NCT02721641</DOCNO>
	<brief_summary>This study design provide continued access intravenous ( IV ) Herceptin evaluate long-term outcome overall safety participant stable disease human epidermal growth factor 2 ( HER2 ) -overexpressing metastatic locally advanced cancer complete prior study IV Herceptin .</brief_summary>
	<brief_title>A Continuation Study Herceptin ( Trastuzumab ) Participants With Metastatic Locally Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Ongoing participant complete global Rochesponsored Herceptin trial Participants enrol Rochesponsored Herceptin trial least stable disease ( whose disease recur ) Herceptin therapy end leadin trial Available study termination data ( include tumor assessment laboratory data ) Case Report Form leadin trial Judged eligible investigator follow thorough risk/benefit assessment , sign chronic heart failure develop leadin trial Pregnant nursing woman Women childbearing potential unless use effective contraception determine investigator Severe dyspnea rest require supplementary oxygen therapy Severe uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>